Diligence memo · auto-generated · as of July 2, 2026
Syenex, Inc.
Syenex, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Syenex, Inc. operates in Biotechnology, based in Evanston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Syenex, Inc. has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.7M on 2025-01-13.
Most recent recorded round closed around 2025-01-13.
Valuation (modeled)modeled
Provath models Syenex, Inc. at approximately $35M (range $9.4M–$67M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.24× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 18 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 62% of Biotechnology peers (4293 compared).
Modeled value ranks above 38% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.